↩ Return to the full treatment list

Treatment Access Solution

A collaboration with Pfizer

Xalkori® (crizotinib)

The Max Foundation and Pfizer have entered into an agreement to provide select oncology medicines, including Xalkori®, to patients living in lower-income countries with no existing access to these products, and are proud of this collaboration to bring lifesaving cancer care to underserved patients around the world.

Xalkori® is used to treat anaplastic lymphoma kinase (ALK) and ROS1-positive non-small cell lung cancer.

Requests for Xalkori® must meet specified criteria. View our global map and click on individual countries to learn where this collaboration is operating today. Contact us for more information about access to Xalkori® in these countries.

Go on the Patient Journey

Join Tony as he shares his story of learning about his cancer, gaining access to life-saving medication, and connecting with a community of care.
Follow Tony's Journey